What is the application of peptides in the diagnosis and treatment of lung cancer

On May 21, 2021, Shell Search announced that Mr. Zuo Hui, the founder and chairman of the company, died on May 20, 2021 due to an unexpected deterioration of his illness.

According to the Wuhan Morning News, insiders in Shell Looking for a house said that the news is true and the internal mailbox has also been announced, “Lung cancer should be some time away.”

Lung cancer is one of the malignant tumors with the fastest increase in morbidity and mortality and the greatest threat to people’s health and life. According to data issued by the International Agency for Research on Cancer of the World Health Organization, China has the largest number of new cancers in the world in 2020, about 4.57 million, of which lung cancer ranks first in the number of new cases.

In 2020 alone, the global new incidence of lung cancer will reach 2.2 million cases, while the number of new lung cancer cases in China in 2020 will reach 820,000, and the number of deaths will be 710,000.

In recent years, the incidence of lung cancer has increased significantly, and it has become the type of cancer with the largest number of cases and deaths in my country. What is even more frightening is that more than two-thirds of these first-time patients have entered the advanced stage! Lung cancer has endangered people’s lives to a great extent.

Lung cancer can be divided into small cell lung cancer and non-small cell lung cancer. It is the malignant tumor with the highest morbidity and mortality in the world.

The main treatment options for lung cancer are radiotherapy, chemotherapy and surgery. Although it can increase the survival rate of patients, the side effects of radiotherapy and chemotherapy are obvious, and the tolerance is poor. The current new technology for cancer treatment is molecular targeted therapy, and finding new diagnosis and treatment methods is still the key to the treatment of lung cancer. Studies have shown that the study of tumor-targeting peptides has become a milestone in tumor treatment.

For the diagnosis and treatment of lung cancer, a polypeptide used for the diagnosis and treatment of lung cancer, a carrier polypeptide for lung cancer targeting, a polypeptide for inhibiting the growth of lung cancer cells, and a related polypeptide hormone or growth factor for the growth of lung cancer have been produced.

Among them, the early detection of lung cancer is the key to treatment. The lung cancer targeting peptide is labeled with fluorescent substances to diagnose lung cancer. At the same time, it can also determine whether the lung cancer has moved and dynamically observe the effect.

On the other hand, the drug can be combined with a targeted polypeptide to target the treatment of lung cancer. After the targeted peptide is combined with the therapeutic peptide, lung cancer can be treated without the use of drugs, which will eliminate the toxic side effects of the original drug treatment of lung cancer.

At the same time, targeted polypeptides can be used as tool molecules to provide convenience for the research of lung cancer signal transduction. Finally, in the study of the pathogenesis of lung cancer, by targeting peptides, it is possible to find out which genes produce specific antigens on the surface of lung cancer.

Recently, the research group Wang Ben of the Institute of Translational Medicine of Zhejiang University/The Second Affiliated Hospital of Zhejiang University School of Medicine published an article in Advanced Functional Materials, reporting a calcification-inducing polypeptide (CiP) targeted for non-small cell lung cancer It can enrich calcium ions in the collective fluid under physiological conditions, induce calcification of lung cancer cells, and make early detection and elimination of lung cancer possible.

Targeting peptide-induced calcification of lung cancer cells can improve the contrast of lung cancer on CT, and realize the CT diagnosis of early lung cancer and the differential diagnosis from benign lung nodules. One end of the targeting peptide has targeting selectivity and can selectively adhere to lung cancer cell membranes, and the other end of polyglutamic acid has the ability to induce calcification of lung cancer cells. Due to good targeting, this calcification process only occurs on lung cancer cells, and has no significant effect on normal lung epithelial cells.

The research team also used co-immunoprecipitation and protein profiling to identify the targeting site of the lung cancer cell targeting peptide determined by phage display peptide technology as the tyrosine kinase receptor (EPHA2), revealing that EPHA2 is a lung cancer cell The potential role of surface carcinoembryonic antigen.

Target-induced calcification of lung cancer cells can not only inhibit the proliferation, migration and invasion of cancer cells, but also promote cancer cell death by affecting the energy metabolism and glycolysis of lung cancer cells. This new method of killing cancer cells is different from traditional chemotherapy. It does not depend on the uptake of chemotherapy drugs by cancer cells. It may have a new killing effect on chemotherapy-resistant cancer cells and has a good clinical transformation prospect.

At present, peptides have played a huge advantage in the diagnosis, early detection and treatment of lung cancer. It is hoped that with the continuous advancement of science, mankind will be able to defeat lung cancer as the “king of cancer” at an early date. …